Friday, September 17, 2021

W.R. Grace lays out $570M for Albemarle unit to bolster pharma portfolio, API manufacturing

Just weeks after specialty chemicals player W.R. Grace received a buyout offer, the company is turning around to strike an M&A deal of its own. The company revealed that it’s beefing up its pharma and manufacturing muscle with the $570 million purchase of an Albemarle unit.

Grace is picking up Albemarle’s Fine Chemistry Services business for $570 million, including $300 million in cash. Albemarle is set to receive the remaining $270 million in equity of a newly-minted Grace subsidiary, the companies said.

Through the deal, Grace will take control of certain Albemarle drugs, plus analytical, regulatory and manufacturing services. It’s also getting its hands on Albemarle’s facilities in Tyrone, Pennsylvania, and South Haven, Michigan, which turn out drug ingredients, advanced intermediates and FDA-approved additives, Albemarle said in a separate release.


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

In all, the deal is set to position Grace as a “fully-integrated” CDMO, the company said.

RELATED: Perrigo’s generics split is back on the docket, thanks to $1.55B Altaris offer 

Albemarle’s analytical, regulatory and manufacturing services should boost Grace’s pharma and consumer business, which it trumpets as the fastest-growing segment of its materials technologies group. That unit, which runs complementary to Grace’s catalysts technologies arm, covers chromatographic resins, formulation excipients and drug delivery, plus intermediates and active pharmaceutical ingredients (API). Meanwhile, Grace says the deal will allow it expand its foothold in the oncology, diabetes, cardiovascular and antiviral markets, too. 

Albemarle’s Fine Chemistry Services business comes equipped to tackle small molecule CDMO work from the pre-clinical stages through commercial manufacturing, the companies said. 

If the deal closes in the second quarter as planned, Grace figures the Albemarle group will add around $60 million to its full-year earnings before interest and taxes. 

RELATED: Catalent continues cell and gene therapy push with deal for Belgian CDMO

Albemarle, for its part, says the sale will help refine its focus on its “core, growth-oriented business segments,” CEO Kent Masters said in a release. 

Separately, Grace could soon have new ownership. In mid-January, the company received an unsolicited offer from investment platform 40 North Management to buy out Grace for $65 per share in cash. The company said it was “willing to discuss” a sale, so long as the proposed price “reflects the full value of Grace for its shareholders,” president and CEO Hudson La Force wrote in a prepared response to 40 North. 

The company could quickly deliver 40 North the information needed for a full valuation, La Force said at the time. Grace on Thursday said it was continuing to review alternatives as it weighs a number of potential opportunities, The Baltimore Sun reported. 

Source link

Latest Articles

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...

Understand Key Account Management

INTRODUCTION: Key Account Management is the essential showcasing approach that gives a successful, useful, and rather basic technique for...

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...